• 1
    Sander JW. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993;34: 100716.
  • 2
    Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999;34: 10922.
  • 3
    Scheffer GL, Scheper RJ. Drug resistance molecules: lessons from oncology. Novartis Found Symp 2002;243: 1931; discussion 31–7.
  • 4
    Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2: 4858.
  • 5
    Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301: 714.
  • 6
    Sun H, Dai H, Shaik N, et al. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 2003;55: 83105.
  • 7
    Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol2003;16: 197201.
  • 8
    Kedersha NL, Rome LH. Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 1986;103: 699709.
  • 9
    Scheffer GL, Flens MJ, Giaccone G, et al. Major vault protein LRP-related multidrug resistance. Am J Pathol 1996;148: 87787.
  • 10
    Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36: 16.
  • 11
    Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999;10: 343741.
  • 12
    Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42: 15016.
  • 13
    Sisodiya SM, Lin WR, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125: 2231.
  • 14
    Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003;118: 41729.
  • 15
    Aronica E, Gorter JA, Van Vliet EA, et al. Overexpression of the human major vault protein in gangliogliomas. Epilepsia 2003;44: 110.
  • 16
    Engel JJ. Outcome with respect to epileptic seizures. In: EngelJJJr, ed. Surgical treatment of epilepsy. New York : Raven Press, 1987: 55371.
  • 17
    Flens MJ, Izquierdo MA, Scheffer GL, et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994;54: 455763.
  • 18
    Scheffer GL, Kool M, Heijn M, et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 2000;60: 526977.
  • 19
    Schroeijers AB, Scheffer GL, Reurs AW, et al. Detection of the Mr 110,000 lung resistance-related protein LRP/MVP with monoclonal antibodies. J Histochem Cytochem 2001;49: 137985.
  • 20
    Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002;55: 3329.
  • 21
    Geurts JJ, Wolswijk G, Bo L, et al. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 2003;126: 175566.
  • 22
    Rao VV, Anthony DC, Piwnica-Worms D. Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. J Histochem Cytochem 1995;43: 118792.
  • 23
    Romijn HJ, Van Uum JF, Breedijk I, et al. Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy. J Histochem Cytochem 1999;47: 22936.
  • 24
    Thom M, D'Arrigo C, Scaravilli F. Hippocampal sclerosis with hypertrophy of end folium pyramidal cells. Acta Neuropathol 1999;98: 10710.
  • 25
    Blumcke I, Zuschratter W, Schewe JC, et al. Cellular pathology of hilar neurons in Ammon's horn sclerosis. J Comp Neurol 1999;414: 43753.
  • 26
    Thom M, Sisodiya SM, Beckett A, et al. Cytoarchitectural abnormalities in hippocampal sclerosis. J Neuropathol Exp Neurol2002;61: 5109.
  • 27
    Toth K, Vaughan MM, Slocum HK, et al. New immunohistochemical “sandwich”; staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am J Pathol 1994;144: 22736.
  • 28
    Lacueva FJ, Teruel A, Calpena R, et al. Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies. Histopathology 1998;32: 32834.
  • 29
    Blom DJ, Flens MJ, Luyten GP, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996;148: 123747.
  • 30
    Seetharaman S, Barrand MA, Maskell L, et al. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem 1998;70: 11519.
  • 31
    Liu B, Sun D, Xia W, et al. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). J Natl Cancer Inst 1997;89: 15249.
  • 32
    Marroni M, Agarwal M, Kight K, et al. Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene proteins in human brain astrocytes. Neuroscience 2003;121(3):60517.
  • 33
    Cucullo L, Marchi N, Hallene KL, et al. Functional role of multiple drug resistance protein expression in glia and neurons. Glia 2003;449(suppl 2):155.
  • 34
    Lazarowski A, Sevlever G, Taratuto A, et al. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999;21: 7314.
  • 35
    Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002;22: 58339.
  • 36
    Aronica E, Gorter JA, Van Vliet EA, et al. Overexpression of the human major vault protein in gangliogliomas. Epilepsia 2003;44: 116675.
  • 37
    Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003;118: 41729.
  • 38
    Blumcke I, Thom M, Wiestler OD. Ammon's horn sclerosis: a maldevelopmental disorder associated with temporal lobe epilepsy. Brain Pathol 2002;12: 199211.
  • 39
    Borst P, Evers R, Kool M, et al. The multidrug resistance protein family. Biochim Biophys Acta 1999;1461: 34757.
  • 40
    Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003;306: 12431.
  • 41
    Izquierdo MA, Scheffer GL, Flens MJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996;148: 87787.
  • 42
    Kickhoefer VA, Rajavel KS, Scheffer GL, et al. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 1998;273: 89714.
  • 43
    Abbondanza C, Rossi V, Roscigno A, et al. Interaction of vault particles with estrogen receptor in the MCF-7 breast cancer cell. J Cell Biol 1998;141: 130110.
  • 44
    Scheffer GL, Schroeijers AB, Izquierdo MA, et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000;12: 5506.
  • 45
    Berger W, Spiegl-Kreinecker S, Buchroithner J, et al. Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 2001;94: 37782.
  • 46
    Raidl M, Berger W, Schulte-Hermann R, et al. Expression of the lung resistance-related protein in human and rat hepatocarcinogenesis. Am J Physiol Gastrointest Liver Physiol 2002;283: G111724.
  • 47
    Hu Y, Stephen AG, Cao J, et al. A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells. Int J Cancer 2002;97: 14956.
  • 48
    Van Vliet EA, Redeker S, Aronica E, et al. Expression of major vault protein: a vesicular drug transporter, during epileptogenesis in a rat model of temporal lobe epilepsy. Epilepsia 2003;44: 176.
  • 49
    Rome L, Kedersha N, Chugani D. Unlocking vaults: organelles in search of a function. Trends Cell Biol 1991;1: 4750.
  • 50
    Chugani DC, Rome LH, Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 1993;106: 239.
  • 51
    Hamill DR, Suprenant KA. Characterization of the sea urchin major vault protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. Dev Biol 1997;190: 11728.
  • 52
    Kong LB, Siva AC, Rome LH, et al. Structure of the vault, a ubiquitous cellular component review: resolution issues in single-particle reconstruction. Structure 1999;7: 3719.
  • 53
    Litman T, Druley TE, Stein WD, et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58: 93159.
  • 54
    Bates S, Kang M, Meadows B, et al. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar). Cancer 2001;92: 157790.
  • 55
    Kang MH, Figg WD, Ando Y, et al. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. Clin Cancer Res 2001;7: 16107.